Impact of cardiac myosin inhibitor therapy on treatment of hypertension in hypertrophic obstructive cardiomyopathy

11 May 2026 (11:04 - 12:21)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Kenneth Paik

Atrium Health Wake Forest Baptist Medical Center, Winston Salem (United States of America)

6 More presentations in this session

Presentation thumbnail

Association between low-dose aspirin use and serum uric acid levels in older adults: a cross-sectional analysis from the baseline survey of the LAPIS study

Doctor X. Wang (Beijing, CN)

Abstract Slides

Presentation thumbnail

Is there really a clinical benefit to using the new drugs for HFrEF in real life?

Mr V. Martinez Mateo (Alcazar de San Juan, ES)

Abstract Slides

Presentation thumbnail

Head-to-head randomized trials of atorvastatin and rosuvastatin: a systematic review and meta-analysis of changes in inflammatory biomarkers

Doctor A. Omayer (Dubai, AE)

Abstract Slides

Presentation thumbnail

Wild-type transthyretin amyloid cardiomyopathy: spironolactone as a therapeutic option?

Doctor A. Martins (Leiria, PT)

Abstract Slides

Presentation thumbnail

Let's talk about heart failure with preserved ejection fraction and mineralocorticosteroid receptor antagonists: real-world registry data

Doctor D. Besic (Zagreb, HR)

Abstract Slides

Access the full session

Session thumbnail

ePosters in pharmacology and pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

11 May 2026 11:04 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

ESC TV Today

Episode 7: Coronary spasm - Sex differences in heart failure

Congress Session

Challenges in hypertension management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources